Key Drivers
- Cash cushion
- Revenue absent
- Rising leverage
AIAI Summary
AVLN has shifted from survival risk to a long-dated AP01 clinical option: IPO cash extends runway into 2029, but with widening losses and no revenue, upside now hinges almost entirely on convincing efficacy data before ongoing burn forces a weaker future financing decision.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash cushion
- •Revenue absent
- •Rising leverage
AVLN still has a strong cash cushion and near-term liquidity, but zero revenue, persistent losses, rising debt, and deeply negative equity make the stock highly speculative.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Resistance near $33
- •Momentum cooling
AVLN remains in an overall short-term uptrend, but repeated rejections near $33 and the drop to $29.73 show fading momentum and rising volatility, with $28–$29 as key support.
Repeated rallies to about $33 quickly faded into a sharp pullback
Sentiment & News
Key News Insights:
- •Target enrollment
- •Pipeline execution
- •2027 readout
Avalyn Pharma is steadily advancing its inhaled fibrosis pipeline, with target enrollment completed in AP01's Phase 2b trial and topline results expected in 2H 2027.
This supports a positive near-term outlook for Avalyn by reducing development uncertainty and keeping focus on its inhaled pulmonary fibrosis assets
Similar Companies in Healthcare
Other companies in the same sector with AI ratings